Inari Medical, Inc. (NARI) Tops Q4 EPS by 12c, Revenues Beat; Offers 1Q & FY21 Revenues Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Inari Medical Reports Fourth Quarter and Full Year 2020 Financial Results
March 9, 2021 4:01 PM ESTIRVINE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its fourth quarter and full year ended December 31, 2020.
Fourth Quarter Revenue and Business Highlights:
Treated a record 4,600 patients, up 24% sequentially, driving revenue of $48.6 million, which was up 26% sequentially and 144% over the prior year period.Introduction of multiple new products... More